Florian R Schroeck1,2,3,4, Kristine E Lynch5, Zhongze Li6, Todd A MacKenzie4,6, David S Han2,4, John D Seigne2,3, Douglas J Robertson1,4, Brenda Sirovich1,4, Philip P Goodney1,4. 1. Department of Veterans Affairs (VA) Outcomes Group, White River Junction VA Medical Center, White River Junction, Vermont. 2. Section of Urology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire. 3. Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire. 4. The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire. 5. VA Salt Lake City Health Care System and Division of Epidemiology, University of Utah, Salt Lake City, Utah. 6. Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire.
Abstract
BACKGROUND: Surveillance recommendations for patients with low-risk, non-muscle-invasive bladder cancer (NMIBC) are based on limited evidence. The objective of this study was to add to the evidence by assessing outcomes after frequent versus recommended cystoscopic surveillance. METHODS: This was a retrospective cohort study of patients diagnosed with low-risk (low-grade Ta (AJCC)) NMIBC from 2005 to 2011 with follow-up through 2014 from the Department of Veterans Affairs. Patients were classified as having undergone frequent versus recommended cystoscopic surveillance (>3 vs 1-3 cystoscopies in the first 2 years after diagnosis). By using propensity score-adjusted models, the authors estimated the impact of frequent cystoscopy on the number of transurethral resections, the number of resections without cancer in the specimen, and the risk of progression to muscle-invasive cancer or bladder cancer death. RESULTS: Among 1042 patients, 798 (77%) had more frequent cystoscopy than recommended. In adjusted analyses, the frequent cystoscopy group had twice as many transurethral resections (55 vs 26 per 100 person-years; P < .001) and more than 3 times as many resections without cancer in the specimen (5.7 vs 1.6 per 100 person-years; P < .001). Frequent cystoscopy was not associated with time to progression or bladder cancer death (3% at 5 years in both groups; P = .990). CONCLUSIONS: Frequent cystoscopy among patients with low-risk NMIBC was associated with twice as many transurethral resections and did not decrease the risk for bladder cancer progression or death, supporting current guidelines.
BACKGROUND: Surveillance recommendations for patients with low-risk, non-muscle-invasive bladder cancer (NMIBC) are based on limited evidence. The objective of this study was to add to the evidence by assessing outcomes after frequent versus recommended cystoscopic surveillance. METHODS: This was a retrospective cohort study of patients diagnosed with low-risk (low-grade Ta (AJCC)) NMIBC from 2005 to 2011 with follow-up through 2014 from the Department of Veterans Affairs. Patients were classified as having undergone frequent versus recommended cystoscopic surveillance (>3 vs 1-3 cystoscopies in the first 2 years after diagnosis). By using propensity score-adjusted models, the authors estimated the impact of frequent cystoscopy on the number of transurethral resections, the number of resections without cancer in the specimen, and the risk of progression to muscle-invasive cancer or bladder cancer death. RESULTS: Among 1042 patients, 798 (77%) had more frequent cystoscopy than recommended. In adjusted analyses, the frequent cystoscopy group had twice as many transurethral resections (55 vs 26 per 100 person-years; P < .001) and more than 3 times as many resections without cancer in the specimen (5.7 vs 1.6 per 100 person-years; P < .001). Frequent cystoscopy was not associated with time to progression or bladder cancer death (3% at 5 years in both groups; P = .990). CONCLUSIONS: Frequent cystoscopy among patients with low-risk NMIBC was associated with twice as many transurethral resections and did not decrease the risk for bladder cancer progression or death, supporting current guidelines.
Authors: Richard S Matulewicz; Vidit Sharma; Barry B McGuire; Daniel T Oberlin; Kent T Perry; Robert B Nadler Journal: Urol Oncol Date: 2015-06-10 Impact factor: 3.498
Authors: B Leblanc; A J Duclos; F Bénard; J Côté; L Valiquette; J M Paquin; F Mauffette; R Faucher; J P Perreault Journal: J Urol Date: 1999-12 Impact factor: 7.450
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: Brent K Hollenbeck; Zaojun Ye; Rodney L Dunn; James E Montie; John D Birkmeyer Journal: J Natl Cancer Inst Date: 2009-04-07 Impact factor: 13.506
Authors: Samantha Cambier; Richard J Sylvester; Laurence Collette; Paolo Gontero; Maurizio A Brausi; George van Andel; Wim J Kirkels; Fernando Calais Da Silva; Willem Oosterlinck; Stephen Prescott; Ziya Kirkali; Philip H Powell; Theo M de Reijke; Levent Turkeri; Sandra Collette; Jorg Oddens Journal: Eur Urol Date: 2015-07-23 Impact factor: 20.096
Authors: Brent K Hollenbeck; David C Miller; David Taub; Rodney L Dunn; Shukri F Khuri; William G Henderson; James E Montie; Willie Underwood; John T Wei Journal: Cancer Date: 2006-04-01 Impact factor: 6.860
Authors: Florian R Schroeck; A Aziz Ould Ismail; Grace N Perry; David A Haggstrom; Steven L Sanchez; DeRon R Walker; Jeanette Young; Susan Zickmund; Lisa Zubkoff Journal: JCO Oncol Pract Date: 2021-08-31
Authors: Soum D Lokeshwar; Maite Lopez; Semih Sarcan; Karina Aguilar; Daley S Morera; Devin M Shaheen; Bal L Lokeshwar; Vinata B Lokeshwar Journal: Cancers (Basel) Date: 2022-05-24 Impact factor: 6.575
Authors: Kelly K Bree; Yong Shan; Patrick J Hensley; Niyati Lobo; Chengrui Hu; Douglas S Tyler; Karim Chamie; Ashish M Kamat; Stephen B Williams Journal: JAMA Netw Open Date: 2022-03-01
Authors: Rafaela Malinaric; Guglielmo Mantica; Lorenzo Lo Monaco; Federico Mariano; Rosario Leonardi; Alchiede Simonato; André Van der Merwe; Carlo Terrone Journal: Int J Environ Res Public Health Date: 2022-08-05 Impact factor: 4.614
Authors: Michael E Rezaee; Kristine E Lynch; Zhongze Li; Todd A MacKenzie; John D Seigne; Douglas J Robertson; Brenda Sirovich; Philip P Goodney; Florian R Schroeck Journal: PLoS One Date: 2020-03-23 Impact factor: 3.240